Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib
Authors:
- 20 August 2008
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (24) , 4047-4048
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinibClinical and Experimental Medicine, 2007
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacyJournal of Clinical Oncology, 2007
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006